LuMind welcomes three directors to team
In the beginning of 2025, following three nation-wide searches, LuMind IDSC welcomed new team members…
Kate O’NeillApril 11, 2025
Understanding key differences among Alzheimer’s clinical trials in Down syndrome
LuMind IDSC releases guide for families learning about Alzheimer's disease therapies MARCH 14, 2025 -…
RAND report shows benefit of investment in future health outcomes for adults with Down syndrome
10/1/2024 | For immediate release | Contact: Kate O'Neill (koneill@lumindidsc.org) Investment in Alzheimer’s Research Today…
Kate O’NeillSeptember 18, 2024
Updates from AAIC: Down syndrome community boosted by FDA confirmation of label and new anti-amyloid clinical trial
Information revealed at the 2024 AAIC conference on the ACTC-DS-led study in DS-associated Alzheimer's disease…
Kate O’NeillAugust 2, 2024
FDA issues approval for new Alzheimer’s drug Kisunla; Down syndrome community is optimistic
FDA issues approval for Kisunla, new Alzheimer's drug; Down syndrome community optimistic On Tuesday, July…
Kate O’NeillJuly 3, 2024
Down syndrome population will see a clinical trial of new Alzheimer’s drug
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s…
Kate O’NeillJune 11, 2024
Down syndrome collaborators now published in Alzheimer’s and Dementia
“Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome” published in the journal…
Kate O’NeillMarch 15, 2024
LuMind IDSC statement on FDA Advisory Committee for promising Alzheimer’s drug, donanemab
LuMind IDSC is encouraged by today’s news that the U.S. Food and Drug Administration (FDA)…
Kate O’NeillMarch 8, 2024
Message from the CEO: a look ahead to 2024
“I want to enjoy my life for a long time. I want to grow old…
Kate O’NeillJanuary 18, 2024
Progress in 2023 – our annual impact report
Thanks to the extraordinary support and engagement of the Down syndrome community, LuMind IDSC is…
Kate O’NeillDecember 21, 2023
